In the relentless battle against cancer, acute myeloid leukemia (AML) remains one of the most aggressive and enigmatic foes in hematological oncology. Recent advances, however, have unveiled a more detailed map of this malignancy’s molecular underpinnings, leveraging cutting-edge systems biology approaches to chart the initiation and relapse pathways of the disease. A groundbreaking study led by Bahmei, Fadakar, and Tamaddon, published in…

The Hemato-Oncology Testing Market is on a robust growth trajectory, driven by the rising incidence of hematological cancers and the growing demand for advanced diagnostic tools to detect and monitor these conditions. With the increasing awareness surrounding blood cancers and advancements in genomic testing and biomarker-based testing, the market for hemato-oncology testing is expected to expand significantly in the coming years.

In the ever-evolving landscape of oncology, breakthrough treatments continue to reshape the prognosis of complex hematological malignancies. One such promising development emerges from the latest phase II clinical trial investigating the frontline use of acalabrutinib in combination with lenalidomide and rituximab for patients diagnosed with advanced-stage follicular lymphoma exhibiting a high tumor burden. This trial, conducted by Strati et al., elucidates how multimodal immunotherapy regimens can redefine therapeutic paradigms for indolent but often challenging lymphomas.

In the evolving landscape of oncology, particularly for hematological malignancies such as multiple myeloma, the emergence of novel therapeutic modalities marks a significant milestone. The recent findings reported in the pivotal OCEAN and HORIZON trials provide fresh insights into the efficacy and long-term responses associated with the combination therapy of melflufen and dexamethasone. This combination marks an expansion of existing treatment options for patients grappling with relapsed or refractory multiple myeloma, especially in the backdrop of rapid advancements in immunotherapeutic strategies.

At the 13th Annual SOHO Meeting in Houston (Sept 3–6, 2025), Pat Garcia-Gonzalez, CEO of The Max Foundation presented data from our access to CML treatment program, including a treatment free…

Notre projet de recherche est celui d’une monoéquipe multidisciplinaire centré sur les lipides agissant dans/sur les niches tumorales, plus particulièrement sur le métabolisme énergétique/oxydatif et ...

Elizabeth McKenna: PGV001 in Patients with Solid and Hematological Malignancies / AACR, alex rubinsteyn, American Association for Cancer Research, Bhardwaj